Baylor College of Medicine

S1418/BR006: Testing Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple-Negative Breast Cancer (H-42481)

Description

Content

The purpose of this study is to compare the usual approach (no more treatment, additional chemotherapy and radiation after surgery, or radiation alone after surgery) with any effects of receiving 1 year of treatment with pembrolizumab after surgery. This study will allow researchers to know whether treatment with pembrolizumab is better, the same or worse than the usual approach.

Contact

Cristina Coronel

Phone 1: 713–798–1975

IRB: H-42481

Status:

Active

Created:

Back to topback-to-top